Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical)

重组抗RANKL全人单抗（齐鲁制药）

Report date: 2023/09/20 20:05:32

Base Information

Drug NameRecombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical)
Drug Alias Name重组抗RANKL全人单克隆抗体（齐鲁制药）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, PostmenopausalNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A